Περίληψη:
In the Phase III ICARIA-MM study (NCT02990338), the addition of the
anti-CD38 monoclonal antibody isatuximab to pomalidomide and
dexamethasone led to increased progression-free survival and improved
response rates in patients with relapsed/refractory multiple myeloma.
There is an unmet treatment need, particularly among patients with poor
prognoses, including those with high-risk cytogenetics, those who have
renal impairment, those who are elderly and those who are refractory to
prior lines of treatment. In this review, the subgroup analyses from the
ICARIA-MM study, representing subpopulations with poor prognostic
factors, are discussed. Overall, the addition of isatuximab to
pomalidomide and dexamethasone improved progression-free survival and
disease response rates across different subgroups, regardless of
prognostic factor.
Tweetable abstract Isatuximab combination improves progression-free
survival and disease response rates in difficult-to-treat patients with
multiple myeloma.
Lay abstract Currently, the majority of patients with multiple myeloma
are not cured, and current treatments may not be helpful for patients
with poor prognoses, including those with high-risk chromosomal changes,
those who have impaired kidney function, those who are elderly and those
who are refractory to prior treatments. In this review, we will discuss
the benefits of the combination of isatuximab plus pomalidomide and
dexamethasone in these difficult-to-treat patients.
Συγγραφείς:
Richardson, Paul G.
Harrison, Simon J.
Bringhen, Sara and
Schjesvold, Fredrik
Yong, Kwee
Campana, Frank
Le-Guennec,
Solenn
Mace, Sandrine
Dimopoulos, Meletios A.
